跳至主要内容
临床试验/NL-OMON39796
NL-OMON39796已完成2 期

HER2-PET as a diagnostic tool in breast cancer patients with a clinical dilemma - Clinical value of 89Zr-trastuzumab

niversitair Medisch Centrum Groningen0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Patients with a history of histological and/or cytological proven HER2-positive primary breast cancer. HER2-positivity is defined as:
  • a) HER2 immunohistochemical score of 3+, or
  • b) HER2 immunohistochemical score of 2+ and positive FISH for HER2/c-erbB2 amplification.
  • 2. Patients with suspected metastatic disease or local recurrence of HER2-positive breast cancer and a clinical dilemma:
  • a) in whom standard work up with imaging has failed to solve the clinical dilemma (diagnostic/therapeutic), leaving issues with regard to HER2 status of lesions and
  • b) in whom a biopsy is desirable but cannot (easily) be performed due to technical or patient factors or otherwise.
  • 3. Standard work-up with imaging is defined as CT chest and abdomen, bone
  • scintigraphy, as well as FDG-PET.
  • 4. Age >18 years of age.
  • 5. WHO performance status 0-2.

排除标准

  • 1. Pregnant or lactating women.
  • 2. Prior allergic reaction to immunoglobulins or immunoglobulin allergy.

研究者

相似试验